XCancer

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

Description:

This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer treatment

Sponsor:

National Cancer Institute

Phase:

Phase 1

Contacts:

Stephen Michael Hahn (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT00110032 - Click here to see study on

ClinicalTrials.gov

EF5

Isotope(s):
Target(s):
  • Hypoxia
Ligand Class: Small Molecules
Inclusion
  • Amenable to debulking surgery or surgical resection or biopsy as standard initial therapy for the tumor
  • Performance status - Karnofsky 70-100%
  • At least 3 months
  • * Histologically confirmed and/or clinical and imaging evidence of a de novo mass that is likely to be a brain tumor
  • WBC count ≥ 2,000/mm\^3
Exclusion

Exclusion Criteria Not Yet Provided